ONC (BeOne Medicines) Valuation Rank


ONC BeOne Medicines Ltd ONC
81 GF Score
Price $280.00
GF Value $366.06
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is BeOne Medicines Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

BeOne Medicines Valuation Rank Related Terms

ONC
81GF Score
BeOne Medicines Ltd ONC
Valuation Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is BeOne Medicines (ONC) Overvalued in 2026?

Based on GuruFocus' analysis, BeOne Medicines stock appears to be undervalued. The current stock price of $280.00 is trading 23.5% below its estimated GF Value™ of $366.06. GuruFocus considers BeOne Medicines to be Modestly Undervalued.

Key valuation signals for ONC:

  • Valuation Rank:
  • GF Value™: $366.06 vs. price of $280.00 (23.5% below fair value)
  • GF Score™: 81/100 with 4 warning signs

No single metric tells the full story. See the ONC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

BeOne Medicines Business Description

Address c/o BeOne Medicines I GmbH, 94 Aeschengraben 27, 21st Floor, Basel, CHE, 4051
Formerly known as BeiGene and founded in 2010 in Beijing, BeOne is a commercial-stage biotech firm that produces oncology therapeutics. The company's main product is Brukinsa, which is a small-molecule drug that treats multiple forms of Non-Hodgkin lymphoma and leukemia. The company conducts drug discovery, runs global clinical trials, and manufactures drugs independently. As of 2025, Brukinsa made up for 74% of total revenue, while it has two other approved commercialized drugs in its portfolio, Beqalzi and Tevimbra. While Brukinsa has a global leadership, the other two drugs generate revenue mostly from China. Based on Brukinsa, BeOne competes with AbbVie and AstraZeneca mainly. The company also has more than 50 drugs in clinical trials in its active pipeline, focused on other cancers.
81GF Score

Get the complete analysis for ONC

Valuation Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$280.00
Price
$366.06
GF Value